Schizoaffective disorder

CooperRiis - Expands Mental Health Care Access in North Carolina - Now In-Network with Blue Cross Blue Shield

Retrieved on: 
Lunedì, Aprile 15, 2024
ACT, Case management, Dialectical behavior therapy, Psychiatry, Bipolar disorder, PTSD, Schizoaffective disorder, Insurance, Partnership, Depression, Psychotherapy, Schizophrenia, DBT, Mental health, Personality, Helsinki University Central Hospital, Commitment, Hospital, Therapy, PHP, Anxiety

ASHEVILLE, N.C., April 15, 2024 /PRNewswire-PRWeb/ -- CooperRiis, a non-profit mental health treatment program, announces it is now in-network with Blue Cross Blue Shield of North Carolina with two of its leading programs:

Key Points: 
  • CooperRiis, a non-profit mental health treatment program, announces it is now in-network with Blue Cross Blue Shield of North Carolina with two of its leading programs.
  • By adding additional insurance plans, CooperRiis offers more North Carolinians access to ground-breaking mental health care.
  • The PHP is a day program that offers stabilization following hospitalization with more intensive care than a doctor's or therapist's office.
  • We believe that everyone deserves access to quality mental health care and this partnership with Blue Cross Blue Shield of North Carolina is a significant step towards realizing that vision."

CooperRiis Healing Community Introduces Direct Admission into Transitional Living Program

Retrieved on: 
Lunedì, Marzo 18, 2024
Personality, Depression, Schizophrenia, Learning, Environment, Mental health, Bipolar disorder, Helsinki University Central Hospital, Partial hospitalization, Anxiety, Schizoaffective disorder, Transition, PTSD, Nursing

ASHEVILLE, N.C., March 18, 2024 /PRNewswire-PRWeb/ -- CooperRiis Healing Community, a leading mental health non-profit organization dedicated to providing compassionate and holistic care, is thrilled to announce the launch of Direct Admissions into their Transitional Living Program. This new offering expands their integrated system of care, furthering their commitment to supporting individuals on their journey to mental wellness bypassing the need to begin treatment at their residential level of care.

Key Points: 
  • CooperRiis Healing Community, a leading mental health non-profit organization dedicated to providing compassionate and holistic care, is thrilled to announce the launch of Direct Admissions into their Transitional Living Program.
  • ASHEVILLE, N.C., March 18, 2024 /PRNewswire-PRWeb/ -- CooperRiis Healing Community, a leading mental health non-profit organization dedicated to providing compassionate and holistic care, is thrilled to announce the launch of Direct Admissions into their Transitional Living Program.
  • We are excited to introduce direct admission into our Transitional Living Program.
  • Individuals interested in learning more about the Transitional Living Program and the admissions process at CooperRiis Healing Community are encouraged to visit the organization's website or contact admissions directly.

Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia

Retrieved on: 
Giovedì, Gennaio 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Schizoaffective disorder, Bipolar disorder, Cmin, Safety, Food, Cmax, Risperidone, Schizophrenia, Pharmaceutical industry

Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder.

Key Points: 
  • Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder.
  • The pivotal study included participants with schizophrenia and schizoaffective disorder who were on a stable dose of an oral antipsychotic medication at the start of the study.
  • The study assessed oral weekly risperidone 15 mg and 45 mg, equivalent to 2 mg and 6 mg daily Risperdal, respectively.
  • “We are eager to bring long-acting oral therapies to patients and are focused on advancing oral weekly risperidone into its remaining pivotal safety trial in 2024.”

Schizoaffective Disorder Drug Pipeline Research Report 2023 Featuring Lyndra Therapeutics, Luye Pharma Group, BioXcel Therapeutics, & Reviva Pharma - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Novembre 9, 2023
Health, Pharmaceutical, FDA, III, Therapy, II, US Foods, News, Discovery, Acquisition, Disease, Disorder, Clinical trial, Schizophrenia, Mergers and acquisitions, Risperidone, NDA, Dietary supplement, Pharmaceutical industry, Schizoaffective disorder

The "Schizoaffective Disorder - Pipeline Insight, 2023" report offers comprehensive insights into the Schizoaffective disorder pipeline landscape, encompassing information on more than 4 companies and over 4 pipeline drugs.

Key Points: 
  • The "Schizoaffective Disorder - Pipeline Insight, 2023" report offers comprehensive insights into the Schizoaffective disorder pipeline landscape, encompassing information on more than 4 companies and over 4 pipeline drugs.
  • The report delivers a thorough understanding of the current scenario and growth prospects within the Schizoaffective disorder indication.
  • It furnishes an extensive overview of the Schizoaffective disorder pipeline landscape, including information on the disease itself and treatment guidelines.
  • The assessment section of the report includes a comprehensive commercial assessment of Schizoaffective disorder, as well as a clinical evaluation of the pipeline products currently in development.

New Study Finds At Least Twice as Many US Adults Experience Schizophrenia Spectrum Disorders Than Previously Thought

Retrieved on: 
Martedì, Giugno 27, 2023
Columbia University, Prison, Structured Clinical Interview for DSM, Duke University, Substance Abuse, Spectrum, University, Prevalence, Life, Harvard University, Schizophrenia, Disability, Schizophreniform disorder, SAMHSA, Treatment Advocacy Center, Diagnosis, Substance Abuse and Mental Health Services Administration, Schizoaffective disorder, DSM-IV codes, Research, Life expectancy, RTI, Mental, New York State Psychiatric Institute, RESEARCH, Fifth Edition, Comorbidity, University of Washington School of Medicine, DSM-5, Health, Mental health, PARK, RTI International, Pharmaceutical industry, Nursing, Dietary supplement

Schizophrenia spectrum disorders include schizophrenia, schizoaffective disorder and schizophreniform disorder.

Key Points: 
  • Schizophrenia spectrum disorders include schizophrenia, schizoaffective disorder and schizophreniform disorder.
  • "The MDPS finding that schizophrenia spectrum disorders may be more prevalent than previously thought is especially important," said Heather Ringeisen , Ph.D., vice president, health of populations at RTI and principal investigator of the project.
  • "People with a schizophrenia spectrum disorder experience high levels of disability that present significant challenges in all aspects of their life."
  • Treatments for schizophrenia spectrum disorders exist but not all people who are diagnosed receive effective treatment.

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

Retrieved on: 
Lunedì, Maggio 22, 2023
Volunteering, Human, Central nervous system, Metabolism, Schizophrenia, American Society for Pharmacology and Experimental Therapeutics, New Drug Application, PME, NDA, CYP3A, Schizoaffective disorder, SAD, Cmax, Experiment, CNS, Clozapine, CYP3A4, Risperidone, Plasma, Aripiprazole, Animal, DSM-IV codes, Patient, Phenytoin, Itraconazole, Mouse, State, Glucuronic acid, Pharmacology, Lurasidone, Society, Brexpiprazole, Cariprazine, Safety, ASPET, Vaccine, Pharmaceutical industry, Brilaroxazine

CUPERTINO, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented two posters on promising clinical pharmacology and safety studies data on the novel serotonin-dopamine stabilizer brilaroxazine at the American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023 annual meeting took place in St. Louis, Missouri, USA, May 18-21, 2023. The ASPET posters are available at revivapharma.com/publications. Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.

Key Points: 
  • Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.
  • “These data support the concomitant use of brilaroxazine with other medications metabolized by CYP3A4 as most schizophrenia patients take multiple concomitant medications.
  • As part of the required clinical studies for New Drug Application (NDA), the drug-drug interactions between brilaroxazine with a strong CYP3A4 inhibitor (itraconazole) and inducer (phenytoin) were evaluated.
  • Brilaroxazine single dose co-administered with phenytoin at steady-state resulted in decrease of ~33%, 57% and 54% in brilaroxazine Cmax, AUC0-t, and AUC0∞, respectively.

Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder

Retrieved on: 
Martedì, Maggio 9, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Injection, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Donald, Hospital, Schizophrenia, Clinical trial, Medicine, Schizoaffective disorder, Bipolar I disorder, Risperidone, Patient, Clinical research, Psychiatry, Therapy, Mental health, Caregiver, Safety, Pharmaceutical industry, Lyndra Littles

Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005).

Key Points: 
  • Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005).
  • Lyndra is developing LYN-005 to provide a new treatment option for patients living with schizophrenia, schizoaffective disorder and bipolar I disorder.
  • Lyndra’s LYNX™ drug delivery platform is designed to enable a week-long dose of risperidone to be delivered in a single oral capsule.
  • The oral daily form of risperidone is one of the most prescribed treatments for people living with schizophrenia and bipolar I disorder.

MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)

Retrieved on: 
Giovedì, Maggio 4, 2023
Biotechnology, Pharmaceutical, Health, Teva Pharmaceuticals, Olanzapine, Schizophrenia, Pharmacokinetics, Schizoaffective disorder, BEPO, Trial of the century, U.S. FDA, Patient, FDA, Safety, SIRS, Generic drug, Pharmaceutical industry, Teva

After injection, mdc-TJK (TEV-44749) reached a therapeutic concentration within a day and maintained it throughout the 28-day dosing interval.

Key Points: 
  • After injection, mdc-TJK (TEV-44749) reached a therapeutic concentration within a day and maintained it throughout the 28-day dosing interval.
  • The pharmacokinetic analysis to be presented at SIRS informed the doses of the pivotal Phase 3 clinical study initiated in January 2023 by Teva.
  • Now we are awaiting the safety and efficacy results of the ongoing Phase 3 study.
  • Several presentations related to studies that supported the regulatory development and the approval of UZEDY will also be communicated at SIRS 2023 by Teva.

Sacramento Mental Health Attorney Ken Rosenfeld Gets Treatment and Probation, Not Prison, for San Diego Client Suffering from Schizophrenia

Retrieved on: 
Giovedì, Aprile 27, 2023
California Mental Health Services Act, St. Michael's Indian Residential School (Alert Bay), Elder abuse, Schizophrenia, San Diego County, California, SMI, Mental health, Schizoaffective disorder, History, SAN, Assault, Nursing

SAN DIEGO, April 27, 2023 /PRNewswire-PRWeb/ -- The Rosenfeld Law Firm announces that a mental health client charged with felony assault, elder abuse, and committing another felony while out on bail (Case # SCD291334) will receive mental health treatment rather than mandatory time in state prison. As a result of the efforts of Sacramento Mental Health Attorney Ken Rosenfeld, the client has been accepted for placement into San Diego's Behavioral Health Court, a collaborative courts program for mental health treatment affiliated with the San Diego Superior Court.

Key Points: 
  • Successfully arguing that his client suffers from schizophrenia, California Mental Health Attorney Ken Rosenfeld of The Rosenfeld Law Firm negotiated Mr. B's acceptance into San Diego's Behavioral Health Court program and three years of formal probation.
  • SAN DIEGO, April 27, 2023 /PRNewswire-PRWeb/ -- The Rosenfeld Law Firm announces that a mental health client charged with felony assault, elder abuse, and committing another felony while out on bail (Case # SCD291334) will receive mental health treatment rather than mandatory time in state prison.
  • As a result of the efforts of Sacramento Mental Health Attorney Ken Rosenfeld, the client has been accepted for placement into San Diego's Behavioral Health Court, a collaborative courts program for mental health treatment affiliated with the San Diego Superior Court.
  • Rosenfeld stated that his Sacramento firm was pleased to have won a mental health case as an outside firm in San Diego.

CooperRiis Healing Community Launches Partial Hospitalization Program

Retrieved on: 
Martedì, Aprile 11, 2023
ACT, Depression, Hospital, Helsinki University Central Hospital, Schizophrenia, Commitment, Anxiety, Dialectical behavior therapy, Schizoaffective disorder, Psychotherapy, DBT, Personality, PHP, Partial, Case management, Therapy, Mental health, Psychiatry, Bipolar disorder, PTSD, Nursing

ASHEVILLE, N.C., April 11, 2023 /PRNewswire/ -- CooperRiis Healing Community, a non-profit mental health treatment program introduces its new "Partial Hospitalization Program", or PHP, launching May 30, 2023, in downtown Ashville.

Key Points: 
  • ASHEVILLE, N.C., April 11, 2023 /PRNewswire/ -- CooperRiis Healing Community, a non-profit mental health treatment program introduces its new "Partial Hospitalization Program", or PHP, launching May 30, 2023, in downtown Ashville.
  • The program will be highly structured and offer short-term day treatment, five hours a day, five days a week, and runs approximately 4-6 weeks.
  • CooperRiis Healing Community introduces new Partial Hospitalization Program, or PHP, launching May 30, 2023 in Ashville
    This year marks the 20th anniversary of CooperRiis, and since its opening, they have grown to five levels of care in an integrated system; four of those levels are offered in the Asheville area.
  • Additionally, the PHP members will be offered community integration opportunities within CooperRiis' other levels of care.